Diane West

At the 101st American Association for Cancer Research (AACR) Annual Meeting in Washington, DC, in April, Pfizer presented a broad overview of its current oncology pipeline.

The ability to predict how the course of cancer will likely play out in an individual patient based on genetic factors is already changing the way certain cancers are approached. As highlighted at the recent Biomarker World Conference in Philadelphia, clinical oncologists have an increasingly integral role.

Key findings from the 2008 ASCO Breast Cancer conference; updates on goserelin, capecitabine, docetaxel & lapatinib.

Breast cancer in general is not openly discussed in Malaysia, but this may be changing.